þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware | 95-4097995 | |
(State or other jurisdiction of | (I.R.S. Employer | |
incorporation or organization) | Identification No.) |
Large accelerated filer þ
|
Accelerated filer o | Non-accelerated filer o | Smaller reporting company o | |||
(Do not check if a smaller reporting company) |
Page | ||||||||
Number | ||||||||
1 | ||||||||
2 | ||||||||
3 | ||||||||
4 | ||||||||
5 | ||||||||
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations |
15 | |||||||
Item 3. Quantitative and Qualitative Disclosures About Market Risk |
28 | |||||||
Item 4. Controls and Procedures |
28 | |||||||
Part II. Other Information |
||||||||
Item 1. Legal Proceedings |
29 | |||||||
Item 1A. Risk Factors |
29 | |||||||
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds |
29 | |||||||
Item 3. Defaults Upon Senior Securities |
29 | |||||||
Item 5. Other Information |
29 | |||||||
Item 6. Exhibits |
29 | |||||||
Signature |
30 | |||||||
Exhibit Index |
31 | |||||||
Exhibit 31.1 | ||||||||
Exhibit 31.2 | ||||||||
Exhibit 32.1 | ||||||||
EX-101 INSTANCE DOCUMENT | ||||||||
EX-101 SCHEMA DOCUMENT | ||||||||
EX-101 CALCULATION LINKBASE DOCUMENT | ||||||||
EX-101 LABELS LINKBASE DOCUMENT | ||||||||
EX-101 PRESENTATION LINKBASE DOCUMENT | ||||||||
EX-101 DEFINITION LINKBASE DOCUMENT |
June 30, | December 31, | |||||||
2011 | 2010 | |||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 155,783 | $ | 97,126 | ||||
Trade accounts receivable, less allowance for
uncollectible accounts of $13,197 and $13,801
at June 30, 2011 and December 31, 2010,
respectively |
54,478 | 49,224 | ||||||
Inventory |
42,682 | 40,760 | ||||||
Prepaid expense and other |
22,701 | 21,138 | ||||||
Deferred income taxes |
20,330 | 19,019 | ||||||
Prepaid income taxes |
11,554 | 19,047 | ||||||
Total current assets |
307,528 | 246,314 | ||||||
Property and equipment, less accumulated
depreciation and amortization of$218,735
and $198,157 at June 30, 2011 and December
31, 2010, respectively |
341,070 | 331,687 | ||||||
Goodwill |
1,100,858 | 1,092,480 | ||||||
Other intangible assets, net |
43,625 | 46,986 | ||||||
Notes receivable, net |
6,226 | 6,429 | ||||||
Deferred financing costs, net |
5,926 | 6,700 | ||||||
Other |
38,179 | 35,826 | ||||||
Total assets |
$ | 1,843,412 | $ | 1,766,422 | ||||
Liabilities and Equity |
||||||||
Current liabilities: |
||||||||
Current portion of long-term debt |
$ | 27,774 | $ | 28,101 | ||||
Accounts payable |
30,708 | 31,970 | ||||||
Accrued payroll and related liabilities |
51,710 | 35,754 | ||||||
Other accrued liabilities |
41,646 | 45,769 | ||||||
Total current liabilities |
151,838 | 141,594 | ||||||
Long-term debt, less current portion |
485,130 | 498,935 | ||||||
Deferred income taxes |
92,367 | 82,131 | ||||||
Other liabilities |
26,512 | 28,478 | ||||||
Total liabilities |
755,847 | 751,138 | ||||||
Commitments and contingencies |
||||||||
Redeemable noncontrolling interests |
6,257 | 5,799 | ||||||
Preferred stock, par value $0.001, 11,000 shares
authorized, none outstanding |
| | ||||||
VCA Antech, Inc. stockholders equity: |
||||||||
Common stock, par value $0.001, 175,000 shares
authorized, 86,595 and 86,179 shares outstanding
as of June 30, 2011 and December 31, 2010,
respectively |
87 | 86 | ||||||
Additional paid-in capital |
351,206 | 347,848 | ||||||
Retained earnings |
718,704 | 650,253 | ||||||
Accumulated other comprehensive income |
1,178 | 737 | ||||||
Total VCA Antech, Inc. stockholders equity |
1,071,175 | 998,924 | ||||||
Noncontrolling interests |
10,133 | 10,561 | ||||||
Total equity |
1,081,308 | 1,009,485 | ||||||
Total liabilities and equity |
$ | 1,843,412 | $ | 1,766,422 | ||||
1
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Revenue |
$ | 376,105 | $ | 353,919 | $ | 731,228 | $ | 684,653 | ||||||||
Direct costs |
279,273 | 260,435 | 554,618 | 508,374 | ||||||||||||
Gross profit |
96,832 | 93,484 | 176,610 | 176,279 | ||||||||||||
Selling, general and administrative expense |
26,663 | 41,045 | 52,846 | 67,185 | ||||||||||||
Net loss (gain) on sale of assets |
60 | (14 | ) | 149 | 11 | |||||||||||
Operating income |
70,109 | 52,453 | 123,615 | 109,083 | ||||||||||||
Interest expense, net |
4,575 | 2,778 | 8,594 | 5,945 | ||||||||||||
Other income |
(67 | ) | (335 | ) | (9 | ) | (310 | ) | ||||||||
Income before provision for income taxes |
65,601 | 50,010 | 115,030 | 103,448 | ||||||||||||
Provision for income taxes |
25,536 | 19,493 | 44,469 | 39,999 | ||||||||||||
Net income |
40,065 | 30,517 | 70,561 | 63,449 | ||||||||||||
Net income attributable to noncontrolling interests |
453 | 1,113 | 2,110 | 2,110 | ||||||||||||
Net income attributable to VCA Antech, Inc |
$ | 39,612 | $ | 29,404 | $ | 68,451 | $ | 61,339 | ||||||||
Basic earnings per share |
$ | 0.46 | $ | 0.34 | $ | 0.79 | $ | 0.71 | ||||||||
Diluted earnings per share |
$ | 0.45 | $ | 0.34 | $ | 0.78 | $ | 0.70 | ||||||||
Weighted-average shares outstanding
for basic earnings per share |
86,535 | 86,041 | 86,445 | 85,933 | ||||||||||||
Weighted-average shares outstanding
for diluted earnings per share |
87,304 | 87,178 | 87,303 | 87,069 | ||||||||||||
2
Accumulated | ||||||||||||||||||||||||||||
Additional | Other | |||||||||||||||||||||||||||
Common Stock | Paid-In | Retained | Comprehensive | Non controlling | ||||||||||||||||||||||||
Shares | Amount | Capital | Earnings | (Loss) Income | Interests | Total | ||||||||||||||||||||||
Balances, December 31, 2009 |
85,584 | $ | 86 | $ | 335,114 | $ | 540,010 | $ | (163 | ) | $ | 11,429 | $ | 886,476 | ||||||||||||||
Net income (excludes $382 and $225 related to redeemable and
mandatorily redeemable noncontrolling interests, respectively) |
| | | 61,339 | | 1,503 | 62,842 | |||||||||||||||||||||
Foreign currency translation adjustment |
| | | | (69 | ) | | (69 | ) | |||||||||||||||||||
Unrealized loss on foreign currency, net of tax |
| | | | (47 | ) | | (47 | ) | |||||||||||||||||||
Unrealized loss on hedging instruments, net of tax |
| | | | (1 | ) | | (1 | ) | |||||||||||||||||||
Losses on hedging instruments reclassified to income, net of tax |
| | | | 233 | | 233 | |||||||||||||||||||||
Distribution to noncontrolling interests |
| | | | | (1,535 | ) | (1,535 | ) | |||||||||||||||||||
Purchase of noncontrolling interests |
| | | | | (233 | ) | (233 | ) | |||||||||||||||||||
Share-based compensation |
| | 5,855 | | | | 5,855 | |||||||||||||||||||||
Issuance of common stock under stock incentive plans |
392 | | 3,770 | | | | 3,770 | |||||||||||||||||||||
Stock repurchases |
| | (2,253 | ) | | | | (2,253 | ) | |||||||||||||||||||
Excess tax benefit from stock options |
| | 331 | | | | 331 | |||||||||||||||||||||
Tax shortfall and other from stock options and awards |
| | (478 | ) | | | | (478 | ) | |||||||||||||||||||
Balances, June 30, 2010 |
85,976 | $ | 86 | $ | 342,339 | $ | 601,349 | $ | (47 | ) | $ | 11,164 | $ | 954,891 | ||||||||||||||
Balances, December 31, 2010 |
86,179 | $ | 86 | $ | 347,848 | $ | 650,253 | $ | 737 | $ | 10,561 | $ | 1,009,485 | |||||||||||||||
Net income (excludes $830 and $227 related to redeemable and
mandatorily redeemable noncontrolling interests, respectively) |
| | | 68,451 | | 1,053 | 69,504 | |||||||||||||||||||||
Foreign currency translation adjustment |
| | | | 296 | | 296 | |||||||||||||||||||||
Unrealized gain on foreign currency, net of tax |
| | | | 145 | | 145 | |||||||||||||||||||||
Distribution to noncontrolling interests |
| | | | | (607 | ) | (607 | ) | |||||||||||||||||||
Purchase of noncontrolling interests |
| | 263 | | | (874 | ) | (611 | ) | |||||||||||||||||||
Share-based compensation |
| | 2,531 | | | | 2,531 | |||||||||||||||||||||
Issuance of common stock under stock incentive plans |
416 | 1 | 2,455 | | | | 2,456 | |||||||||||||||||||||
Stock repurchases |
| | (2,337 | ) | | | | (2,337 | ) | |||||||||||||||||||
Excess tax benefit from stock options |
| | 906 | | | | 906 | |||||||||||||||||||||
Tax shortfall and other from stock options and awards |
| | (460 | ) | | | | (460 | ) | |||||||||||||||||||
Balances, June 30, 2011 |
86,595 | $ | 87 | $ | 351,206 | $ | 718,704 | $ | 1,178 | $ | 10,133 | $ | 1,081,308 | |||||||||||||||
3
Six Months Ended | ||||||||
June 30, | ||||||||
2011 | 2010 | |||||||
Cash flows from operating activities: |
||||||||
Net income |
$ | 70,561 | $ | 63,449 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
Depreciation and amortization |
26,456 | 21,706 | ||||||
Amortization of debt issue costs |
774 | 239 | ||||||
Provision for uncollectible accounts |
2,492 | 3,143 | ||||||
Net loss on sale of assets |
149 | 11 | ||||||
Share-based compensation |
2,531 | 5,855 | ||||||
Deferred income taxes |
10,833 | 6,461 | ||||||
Excess tax benefit from exercise of stock options |
(906 | ) | (331 | ) | ||||
Other |
(202 | ) | (225 | ) | ||||
Changes in operating assets and liabilities: |
||||||||
Trade accounts receivable |
(7,813 | ) | (7,344 | ) | ||||
Inventory, prepaid expense and other assets |
(5,222 | ) | (727 | ) | ||||
Accounts payable and other accrued liabilities |
(7,994 | ) | 13,691 | |||||
Accrued payroll and related liabilities |
16,021 | 12,656 | ||||||
Income taxes |
7,940 | (7,248 | ) | |||||
Net cash provided by operating activities |
115,620 | 111,336 | ||||||
Cash flows from investing activities: |
||||||||
Business acquisitions, net of cash acquired |
(11,804 | ) | (20,078 | ) | ||||
Real estate acquired in connection with business acquisitions |
(1,900 | ) | (1,300 | ) | ||||
Property and equipment additions |
(28,434 | ) | (27,925 | ) | ||||
Proceeds from sale of assets |
140 | 9 | ||||||
Other |
(493 | ) | (162 | ) | ||||
Net cash used in investing activities |
(42,491 | ) | (49,456 | ) | ||||
Cash flows from financing activities: |
||||||||
Repayment of debt |
(14,164 | ) | (12,859 | ) | ||||
Distributions to noncontrolling interest partners |
(1,141 | ) | (2,021 | ) | ||||
Proceeds from issuance of common stock under stock option plans |
2,456 | 3,770 | ||||||
Excess tax benefit from exercise of stock options |
906 | 331 | ||||||
Stock repurchases |
(2,337 | ) | (2,253 | ) | ||||
Other |
(345 | ) | (266 | ) | ||||
Net cash used in financing activities |
(14,625 | ) | (13,298 | ) | ||||
Effect of currency exchange rate changes on cash and cash equivalents |
153 | (6 | ) | |||||
Increase in cash and cash equivalents |
58,657 | 48,576 | ||||||
Cash and cash equivalents at beginning of period |
97,126 | 145,181 | ||||||
Cash and cash equivalents at end of period |
$ | 155,783 | $ | 193,757 | ||||
Supplemental disclosures of cash flow information: |
||||||||
Interest paid |
$ | 8,127 | $ | 6,075 | ||||
Income taxes paid |
$ | 25,696 | $ | 40,787 | ||||
Supplemental schedule of noncash investing and financing activities: |
||||||||
Detail of acquisitions: |
||||||||
Fair value of assets acquired |
$ | 11,889 | $ | 22,202 | ||||
Cash paid for acquisitions |
(11,445 | ) | (19,350 | ) | ||||
Holdbacks |
(500 | ) | (7 | ) | ||||
Liabilities assumed |
$ | (56 | ) | $ | 2,845 | |||
4
5
Animal | Medical | |||||||||||||||
Hospital | Laboratory | Technology | Total | |||||||||||||
Balance as of December 31, 2010 |
$ | 965,999 | $ | 96,818 | $ | 29,663 | $ | 1,092,480 | ||||||||
Goodwill acquired |
10,346 | 6 | | 10,352 | ||||||||||||
Other(1) |
(1,862 | ) | 22 | (134 | ) | (1,974 | ) | |||||||||
Balance as of June 30, 2011 |
$ | 974,483 | $ | 96,846 | $ | 29,529 | $ | 1,100,858 | ||||||||
(1) | Other includes acquisition-price adjustments which consist primarily of an adjustment related to deferred taxes, buy-outs and foreign currency translation adjustments. |
As of June 30, 2011 | As of December 31, 2010 | |||||||||||||||||||||||
Gross | Net | Gross | Net | |||||||||||||||||||||
Carrying | Accumulated | Carrying | Carrying | Accumulated | Carrying | |||||||||||||||||||
Amount | Amortization | Amount | Amount | Amortization | Amount | |||||||||||||||||||
Noncontractual customer
relationships |
$ | 48,319 | $ | (15,791 | ) | $ | 32,528 | $ | 48,686 | $ | (14,188 | ) | $ | 34,498 | ||||||||||
Covenants not-to-compete |
13,285 | (7,961 | ) | 5,324 | 14,459 | (8,311 | ) | 6,148 | ||||||||||||||||
Favorable lease asset |
5,486 | (2,940 | ) | 2,546 | 5,486 | (2,672 | ) | 2,814 | ||||||||||||||||
Trademarks |
3,716 | (1,227 | ) | 2,489 | 3,749 | (986 | ) | 2,763 | ||||||||||||||||
Technology |
2,189 | (1,514 | ) | 675 | 2,189 | (1,447 | ) | 742 | ||||||||||||||||
Client lists |
84 | (21 | ) | 63 | 35 | (14 | ) | 21 | ||||||||||||||||
Total |
$ | 73,079 | $ | (29,454 | ) | $ | 43,625 | $ | 74,604 | $ | (27,618 | ) | $ | 46,986 | ||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Aggregate amortization expense |
$ | 2,604 | $ | 2,187 | $ | 5,259 | $ | 4,341 | ||||||||
6
Remainder of 2011 |
$ | 5,322 | ||
2012 |
9,901 | |||
2013 |
7,669 | |||
2014 |
5,411 | |||
2015 |
3,560 | |||
Thereafter |
11,762 | |||
Total |
$ | 43,625 | ||
June 30, | December 31, | |||||||
2011 | 2010 | |||||||
Deferred revenue |
$ | 6,914 | $ | 8,617 | ||||
Accrued health insurance |
5,268 | 4,970 | ||||||
Deferred rent |
3,780 | 3,456 | ||||||
Accrued consulting fees |
2,760 | 2,760 | ||||||
Holdbacks and earnouts |
2,600 | 2,447 | ||||||
Customer deposits |
1,939 | 2,966 | ||||||
Accrued lab service rebates |
132 | 2,535 | ||||||
Other |
18,253 | 18,018 | ||||||
$ | 41,646 | $ | 45,769 | |||||
7
As of June 30, 2011 | As of December 31, 2010 | |||||||||||||||
Carrying | Fair | Carrying | Fair | |||||||||||||
Value | Value | Value | Value | |||||||||||||
Variable-rate long-term debt |
$ | 481,250 | $ | 483,055 | $ | 493,750 | $ | 496,219 | ||||||||
Weighted- | ||||||||
Average | ||||||||
Stock | Exercise | |||||||
Options | Price | |||||||
Outstanding at December 31, 2010 |
3,323 | $ | 16.45 | |||||
Exercised |
(242 | ) | $ | 10.14 | ||||
Canceled |
(3 | ) | 17.04 | |||||
Outstanding at June 30, 2011 |
3,078 | $ | 16.94 | |||||
Exercisable at June 30, 2011 |
2,739 | $ | 16.93 | |||||
Vested and expected to vest at June 30, 2011 |
3,063 | $ | 16.94 | |||||
8
Grant Date | ||||||||
Weighted- | ||||||||
Average Fair | ||||||||
Value | ||||||||
Shares | Per Share | |||||||
Outstanding at December 31, 2010 |
686,511 | $ | 26.16 | |||||
Granted |
1,148,046 | $ | 20.27 | |||||
Vested |
(268,215 | ) | $ | 30.83 | ||||
Forfeited/Canceled |
(1,896 | ) | $ | 30.35 | ||||
Outstanding at June 30, 2011 |
1,564,446 | $ | 21.03 | |||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Net income attributable to VCA Antech, Inc |
$ | 39,612 | $ | 29,404 | $ | 68,451 | $ | 61,339 | ||||||||
Weighted-average common shares outstanding: |
||||||||||||||||
Basic |
86,535 | 86,041 | 86,445 | 85,933 | ||||||||||||
Effect of dilutive potential common shares: |
||||||||||||||||
Stock options |
647 | 951 | 664 | 943 | ||||||||||||
Nonvested shares |
122 | 186 | 194 | 193 | ||||||||||||
Diluted |
87,304 | 87,178 | 87,303 | 87,069 | ||||||||||||
Basic earnings per share |
$ | 0.46 | $ | 0.34 | $ | 0.79 | $ | 0.71 | ||||||||
Diluted earnings per share |
$ | 0.45 | $ | 0.34 | $ | 0.78 | $ | 0.70 | ||||||||
9
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Net income(1) |
$ | 40,065 | $ | 30,517 | $ | 70,561 | $ | 63,449 | ||||||||
Other comprehensive income: |
||||||||||||||||
Foreign currency translation adjustments |
47 | (236 | ) | 296 | (69 | ) | ||||||||||
Unrealized gain on foreign currency |
48 | (259 | ) | 237 | (77 | ) | ||||||||||
Tax expense |
(19 | ) | 101 | (92 | ) | 30 | ||||||||||
Unrealized loss on hedging instruments |
| | | (2 | ) | |||||||||||
Tax benefit |
| | | 1 | ||||||||||||
Losses on hedging instruments reclassified to income |
| | | 382 | ||||||||||||
Tax benefit |
| | | (149 | ) | |||||||||||
Other comprehensive income |
76 | (394 | ) | 441 | 116 | |||||||||||
Total comprehensive income |
40,141 | 30,123 | 71,002 | 63,565 | ||||||||||||
Comprehensive income attributable to noncontrolling interests(1) |
453 | 1,113 | 2,110 | 2,110 | ||||||||||||
Comprehensive income attributable to VCA Antech, Inc |
$ | 39,688 | $ | 29,010 | $ | 68,892 | $ | 61,455 | ||||||||
(1) | Includes $1.1 million and $607,000 for the six months ended June 30, 2011 and June 30, 2010, respectively, related to redeemable and mandatorily redeemable noncontrolling interests. |
10
Animal | Medical | Intercompany | ||||||||||||||||||||||
Hospital | Laboratory | Technology | Corporate | Eliminations | Total | |||||||||||||||||||
Three Months Ended June 30, 2011 |
||||||||||||||||||||||||
External revenue |
$ | 291,332 | $ | 72,955 | $ | 11,818 | $ | | $ | | $ | 376,105 | ||||||||||||
Intercompany revenue |
| 11,430 | 4,391 | | (15,821 | ) | | |||||||||||||||||
Total revenue |
291,332 | 84,385 | 16,209 | | (15,821 | ) | 376,105 | |||||||||||||||||
Direct costs |
238,392 | 43,716 | 11,419 | | (14,254 | ) | 279,273 | |||||||||||||||||
Gross profit |
52,940 | 40,669 | 4,790 | | (1,567 | ) | 96,832 | |||||||||||||||||
Selling, general and administrative expense |
6,044 | 6,853 | 3,584 | 10,182 | | 26,663 | ||||||||||||||||||
Net loss on sale and disposal of assets |
51 | 7 | 2 | | | 60 | ||||||||||||||||||
Operating income (loss) |
$ | 46,845 | $ | 33,809 | $ | 1,204 | $ | (10,182 | ) | $ | (1,567 | ) | $ | 70,109 | ||||||||||
Depreciation and amortization |
$ | 9,533 | $ | 2,508 | $ | 668 | $ | 685 | $ | (318 | ) | $ | 13,076 | |||||||||||
Capital expenditures |
$ | 13,236 | $ | 1,728 | $ | 258 | $ | 1,627 | $ | (449 | ) | $ | 16,400 | |||||||||||
Three Months Ended June 30, 2010 |
||||||||||||||||||||||||
External revenue |
$ | 267,595 | $ | 73,259 | $ | 13,065 | $ | | $ | | $ | 353,919 | ||||||||||||
Intercompany revenue |
| 9,713 | 1,537 | | (11,250 | ) | | |||||||||||||||||
Total revenue |
267,595 | 82,972 | 14,602 | | (11,250 | ) | 353,919 | |||||||||||||||||
Direct costs |
218,567 | 42,416 | 10,255 | | (10,803 | ) | 260,435 | |||||||||||||||||
Gross profit |
49,028 | 40,556 | 4,347 | | (447 | ) | 93,484 | |||||||||||||||||
Selling, general and administrative expense |
5,673 | 6,527 | 3,404 | 25,441 | | 41,045 | ||||||||||||||||||
Net (gain) loss on sale and disposal of assets |
(35 | ) | | 14 | 7 | | (14 | ) | ||||||||||||||||
Operating income (loss) |
$ | 43,390 | $ | 34,029 | $ | 929 | $ | (25,448 | ) | $ | (447 | ) | $ | 52,453 | ||||||||||
Depreciation and amortization |
$ | 7,630 | $ | 2,396 | $ | 605 | $ | 618 | $ | (250 | ) | $ | 10,999 | |||||||||||
Capital expenditures |
$ | 9,849 | $ | 1,506 | $ | 124 | $ | 858 | $ | (461 | ) | $ | 11,876 |
11
Animal | Medical | Intercompany | ||||||||||||||||||||||
Hospital | Laboratory | Technology | Corporate | Eliminations | Total | |||||||||||||||||||
Six Months Ended June 30, 2011 |
||||||||||||||||||||||||
External revenue |
$ | 561,273 | $ | 142,051 | $ | 27,904 | $ | | $ | | $ | 731,228 | ||||||||||||
Intercompany revenue |
| 21,883 | 7,401 | | (29,284 | ) | | |||||||||||||||||
Total revenue |
561,273 | 163,934 | 35,305 | | (29,284 | ) | 731,228 | |||||||||||||||||
Direct costs |
468,780 | 86,535 | 26,057 | | (26,754 | ) | 554,618 | |||||||||||||||||
Gross profit |
92,493 | 77,399 | 9,248 | | (2,530 | ) | 176,610 | |||||||||||||||||
Selling, general and administrative expense |
12,127 | 13,489 | 7,140 | 20,090 | | 52,846 | ||||||||||||||||||
Net loss on sale and disposal of assets |
129 | 18 | 2 | | | 149 | ||||||||||||||||||
Operating income (loss) |
$ | 80,237 | $ | 63,892 | $ | 2,106 | $ | (20,090 | ) | $ | (2,530 | ) | $ | 123,615 | ||||||||||
Depreciation and amortization |
$ | 19,406 | $ | 4,979 | $ | 1,325 | $ | 1,365 | $ | (619 | ) | $ | 26,456 | |||||||||||
Capital expenditures |
$ | 22,771 | $ | 2,964 | $ | 1,017 | $ | 2,585 | $ | (903 | ) | $ | 28,434 | |||||||||||
Six Months Ended June 30, 2010 |
||||||||||||||||||||||||
External revenue |
$ | 514,263 | $ | 142,659 | $ | 27,731 | $ | | $ | | $ | 684,653 | ||||||||||||
Intercompany revenue |
| 18,493 | 2,668 | | (21,161 | ) | | |||||||||||||||||
Total revenue |
514,263 | 161,152 | 30,399 | | (21,161 | ) | 684,653 | |||||||||||||||||
Direct costs |
423,558 | 84,068 | 21,221 | | (20,473 | ) | 508,374 | |||||||||||||||||
Gross profit |
90,705 | 77,084 | 9,178 | | (688 | ) | 176,279 | |||||||||||||||||
Selling, general and administrative expense |
11,260 | 12,681 | 6,919 | 36,325 | | 67,185 | ||||||||||||||||||
Net (gain) loss on sale and disposal of assets |
(51 | ) | 1 | 54 | 7 | | 11 | |||||||||||||||||
Operating income (loss) |
$ | 79,496 | $ | 64,402 | $ | 2,205 | $ | (36,332 | ) | $ | (688 | ) | $ | 109,083 | ||||||||||
Depreciation and amortization |
$ | 14,982 | $ | 4,809 | $ | 1,206 | $ | 1,199 | $ | (490 | ) | $ | 21,706 | |||||||||||
Capital expenditures |
$ | 22,977 | $ | 2,338 | $ | 206 | $ | 3,185 | $ | (781 | ) | $ | 27,925 | |||||||||||
At June 30, 2011 |
||||||||||||||||||||||||
Total assets |
$ | 1,338,034 | $ | 228,571 | $ | 64,851 | $ | 229,608 | $ | (17,652 | ) | $ | 1,843,412 | |||||||||||
At December 31, 2010 |
||||||||||||||||||||||||
Total assets |
$ | 1,320,619 | $ | 215,483 | $ | 69,082 | $ | 175,297 | $ | (14,059 | ) | $ | 1,766,422 | |||||||||||
12
Income | Redeemable | |||||||
Statement | Noncontrolling | |||||||
Impact | Interests | |||||||
Balance as of December 31, 2009 |
$ | 4,369 | ||||||
Noncontrolling interest |
$ | 382 | ||||||
Redemption value change |
| 382 | ||||||
Formation of noncontrolling interests |
450 | |||||||
Distribution to noncontrolling interests |
(286 | ) | ||||||
Balance as of June 30, 2010 |
$ | 4,915 | ||||||
Balance as of December 31, 2010 |
$ | 5,799 | ||||||
Noncontrolling interest |
$ | 428 | ||||||
Redemption value change |
402 | 830 | ||||||
Distribution to noncontrolling interests |
(372 | ) | ||||||
Balance as of June 30, 2011 |
$ | 6,257 | ||||||
13
14
ITEM 2. | MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
Page | ||||
16 | ||||
16 | ||||
18 | ||||
19 | ||||
20 | ||||
24 |
15
16
Animal Hospitals: |
||||
Beginning of period |
528 | |||
Acquisitions |
6 | |||
Sold, closed or merged |
(4 | ) | ||
End of period |
530 | |||
Laboratories: |
||||
Beginning of period |
50 | |||
Acquisitions |
1 | |||
Created |
1 | |||
End of period |
52 | |||
Consideration: |
||||
Cash (1) |
$ | 11,600 | ||
Holdback |
500 | |||
Fair value of total consideration transferred |
$ | 12,100 | ||
Allocation of the Purchase Price: |
||||
Tangible assets |
$ | 419 | ||
Identifiable intangible assets |
2,129 | |||
Goodwill (2) |
10,352 | |||
Total |
$ | 12,900 | ||
Noncontrolling interest |
(800 | ) | ||
$ | 12,100 | |||
(1) | See the Cash Flows from Investing Activities section in the Liquidity and Capital Resources discussion for reconciliation of cash paid for acquisitions per this schedule to the condensed, consolidated statement of cash flows. | |
(2) | We expect that $10.4 million of the goodwill recorded for these acquisitions as of June 30, 2011 will be fully deductible for income tax purposes. |
17
Consideration: |
||||
Cash paid to bondholders |
$ | 29,532 | ||
Cash paid to shareholders |
7,670 | |||
Cash paid for holdbacks |
750 | |||
Fair value of total consideration transferred |
$ | 37,952 | ||
Allocation of the Purchase Price: |
||||
Tangible assets |
$ | 19,727 | ||
Identifiable intangible assets |
3,074 | |||
Goodwill (1) |
42,930 | |||
Other liabilities assumed |
(27,779 | ) | ||
Total |
$ | 37,952 | ||
(1) | We expect that $6.4 million of goodwill will be fully deductible for income tax purposes. |
18
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Revenue: |
||||||||||||||||
Animal Hospital |
77.5 | % | 75.6 | % | 76.8 | % | 75.1 | % | ||||||||
Laboratory |
22.4 | 23.4 | 22.4 | 23.5 | ||||||||||||
Medical Technology |
4.3 | 4.1 | 4.8 | 4.4 | ||||||||||||
Intercompany |
(4.2 | ) | (3.1 | ) | (4.0 | ) | (3.0 | ) | ||||||||
Total revenue |
100.0 | 100.0 | 100.0 | 100.0 | ||||||||||||
Direct costs |
74.3 | 73.6 | 75.8 | 74.3 | ||||||||||||
Gross profit |
25.7 | 26.4 | 24.2 | 25.7 | ||||||||||||
Selling, general and administrative expense |
7.1 | 11.6 | 7.3 | 9.8 | ||||||||||||
Operating income |
18.6 | 14.8 | 16.9 | 15.9 | ||||||||||||
Interest expense, net |
1.2 | 0.8 | 1.2 | 0.8 | ||||||||||||
Other income, net |
- | (0.1 | ) | - | - | |||||||||||
Income before provision for income taxes |
17.4 | 14.1 | 15.7 | 15.1 | ||||||||||||
Provision for income taxes |
6.7 | 5.5 | 6.1 | 5.8 | ||||||||||||
Net income |
10.7 | 8.6 | 9.6 | 9.3 | ||||||||||||
Net income attributable to noncontrolling interests |
0.2 | 0.3 | 0.2 | 0.3 | ||||||||||||
Net income attributable to VCA Antech, Inc |
10.5 | % | 8.3 | % | 9.4 | % | 9.0 | % | ||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||||||||||||||||||||||||||
% of | % of | % | % of | % of | % | |||||||||||||||||||||||||||||||||||
$ | Total | $ | Total | Change | $ | Total | $ | Total | Change | |||||||||||||||||||||||||||||||
Animal Hospital |
$ | 291,332 | 77.5 | % | $ | 267,595 | 75.6 | % | 8.9 | % | $ | 561,273 | 76.8 | % | $ | 514,263 | 75.1 | % | 9.1 | % | ||||||||||||||||||||
Laboratory |
84,385 | 22.4 | % | 82,972 | 23.4 | % | 1.7 | % | 163,934 | 22.4 | % | 161,152 | 23.5 | % | 1.7 | % | ||||||||||||||||||||||||
Medical Technology |
16,209 | 4.3 | % | 14,602 | 4.1 | % | 11.0 | % | 35,305 | 4.8 | % | 30,399 | 4.4 | % | 16.1 | % | ||||||||||||||||||||||||
Intercompany |
(15,821 | ) | (4.2 | )% | (11,250 | ) | (3.1 | )% | 40.6 | % | (29,284 | ) | (4.0 | )% | (21,161 | ) | (3.0 | )% | 38.4 | % | ||||||||||||||||||||
Total revenue |
$ | 376,105 | 100.0 | % | $ | 353,919 | 100.0 | % | 6.3 | % | $ | 731,228 | 100.0 | % | $ | 684,653 | 100.0 | % | 6.8 | % | ||||||||||||||||||||
19
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||||||||||||||||||||||||||
Gross | Gross | % | Gross | Gross | % | |||||||||||||||||||||||||||||||||||
$ | Margin | $ | Margin | Change | $ | Margin | $ | Margin | Change | |||||||||||||||||||||||||||||||
Animal Hospital |
$ | 52,940 | 18.2 | % | $ | 49,028 | 18.3 | % | 8.0 | % | $ | 92,493 | 16.5 | % | $ | 90,705 | 17.6 | % | 2.0 | % | ||||||||||||||||||||
Laboratory |
40,669 | 48.2 | % | 40,556 | 48.9 | % | 0.3 | % | 77,399 | 47.2 | % | 77,084 | 47.8 | % | 0.4 | % | ||||||||||||||||||||||||
Medical Technology |
4,790 | 29.6 | % | 4,347 | 29.8 | % | 10.2 | % | 9,248 | 26.2 | % | 9,178 | 30.2 | % | 0.8 | % | ||||||||||||||||||||||||
Intercompany |
(1,567 | ) | (447 | ) | (2,530 | ) | (688 | ) | ||||||||||||||||||||||||||||||||
Total gross profit |
$ | 96,832 | 25.7 | % | $ | 93,484 | 26.4 | % | 3.6 | % | $ | 176,610 | 24.2 | % | $ | 176,279 | 25.7 | % | 0.2 | % | ||||||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2011 | 2010 | % Change | 2011 | 2010 | % Change | |||||||||||||||||||
Revenue |
$ | 291,332 | $ | 267,595 | 8.9 | % | $ | 561,273 | $ | 514,263 | 9.1 | % | ||||||||||||
Gross profit |
$ | 52,940 | $ | 49,028 | 8.0 | % | $ | 92,493 | $ | 90,705 | 2.0 | % | ||||||||||||
Gross margin |
18.2 % | 18.3 % | 16.5 % | 17.6 % |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2011 | 2010 | % Change | 2011 | 2010 | % Change | |||||||||||||||||||
Same-store facilities: |
||||||||||||||||||||||||
Orders (1) |
1,621 | 1,692 | (4.2 | )% | 3,094 | 3,237 | (4.4 | )% | ||||||||||||||||
Average revenue per order (2) |
$ | 160.42 | $ | 156.69 | 2.4 | % | $ | 160.62 | $ | 156.74 | 2.5 | % | ||||||||||||
Same-store revenue (1) |
$ | 260,049 | $ | 265,163 | (1.9 | )% | $ | 496,891 | $ | 507,390 | (2.1 | )% | ||||||||||||
Net acquired revenue (3) |
31,283 | 2,432 | 64,382 | 6,873 | ||||||||||||||||||||
Total |
$ | 291,332 | $ | 267,595 | 8.9 | % | $ | 561,273 | $ | 514,263 | 9.1 | % | ||||||||||||
(1) | Same-store revenue and orders were calculated using Animal Hospital operating results, adjusted to exclude the operating results for newly acquired animal hospitals that we did not own as of the beginning of the comparable period in the prior year. Same-store revenue also includes revenue generated by customers referred from our relocated or combined animal hospitals, including those merged upon acquisition. | |
(2) | Computed by dividing same-store revenue by same-store orders. The average revenue per order may not calculate exactly due to rounding. |
20
(3) | Net acquired revenue represents the revenue from those animal hospitals acquired, net of revenue from those animal hospitals sold or closed, on or after the beginning of the comparable period, which was April 1, 2010 for the three month analysis and January 1, 2010 for the six month analysis. Fluctuations in net acquired revenue occur due to the volume, size, and timing of acquisitions and dispositions during the periods from this date through the end of the applicable period. |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2011 | 2010 | % | 2011 | 2010 | % | |||||||||||||||||||
Revenue |
$ | 84,385 | $ | 82,972 | 1.7 | % | $ | 163,934 | $ | 161,152 | 1.7 | % | ||||||||||||
Gross profit |
$ | 40,669 | $ | 40,556 | 0.3 | % | $ | 77,399 | $ | 77,084 | 0.4 | % | ||||||||||||
Gross margin |
48.2 % | 48.9 % | 47.2 % | 47.8 % |
21
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2011 | 2010 | % Change | 2011 | 2010 | % Change | |||||||||||||||||||
Internal growth: |
||||||||||||||||||||||||
Number of requisitions (1) |
3,555 | 3,573 | (0.5 | )% | 6,759 | 6,787 | (0.4 | )% | ||||||||||||||||
Average revenue per requisition (2) |
$ | 23.73 | $ | 23.22 | 2.2 | % | $ | 24.25 | $ | 23.74 | 2.1 | % | ||||||||||||
Total internal revenue (1) |
$ | 84,364 | $ | 82,972 | 1.7 | % | $ | 163,895 | $ | 161,152 | 1.7 | % | ||||||||||||
Acquired revenue (3) |
21 | - | 39 | - | ||||||||||||||||||||
Total |
$ | 84,385 | $ | 82,972 | 1.7 | % | $ | 163,934 | $ | 161,152 | 1.7 | % | ||||||||||||
(1) | Internal revenue and requisitions were calculated using Laboratory operating results, adjusted to exclude the operating results of acquired laboratories that we did not own as of the beginning of the comparable period in the prior year, and adjusted for the impact resulting from any differences in the number of billing days in comparable periods, if applicable. | |
(2) | Computed by dividing internal revenue by the number of requisitions. | |
(3) | Acquired revenue represents the current year period revenue recognized from our acquired laboratories that we did not own as of the beginning of the comparable period in the prior year. |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||
2011 | 2010 | % Change | 2011 | 2010 | % Change | |||||||||||||||||||
Revenue |
$ | 16,209 | $ | 14,602 | 11.0 | % | $ | 35,305 | $ | 30,399 | 16.1 | % | ||||||||||||
Gross profit |
$ | 4,790 | $ | 4,347 | 10.2 | % | $ | 9,248 | $ | 9,178 | 0.8 | % | ||||||||||||
Gross margin |
29.6 % | 29.8 % | 26.2 % | 30.2 % |
22
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||||||||||||||||||||||||||
% of | % of | % | % of | % of | % | |||||||||||||||||||||||||||||||||||
$ | Revenue | $ | Revenue | Change | $ | Revenue | $ | Revenue | Change | |||||||||||||||||||||||||||||||
Animal Hospital |
$ | 6,044 | 2.1 | % | $ | 5,673 | 2.1 | % | 6.5 | % | $ | 12,127 | 2.2 | % | $ | 11,260 | 2.2 | % | 7.7 | % | ||||||||||||||||||||
Laboratory |
6,853 | 8.1 | % | 6,527 | 7.9 | % | 5.0 | % | 13,489 | 8.2 | % | 12,681 | 7.9 | % | 6.4 | % | ||||||||||||||||||||||||
Medical Technology |
3,584 | 22.1 | % | 3,404 | 23.3 | % | 5.3 | % | 7,140 | 20.2 | % | 6,919 | 22.8 | % | 3.2 | % | ||||||||||||||||||||||||
Corporate |
10,182 | 2.7 | % | 25,441 | 7.2 | % | (60.0 | )% | 20,090 | 2.7 | % | 36,325 | 5.3 | % | (44.7 | )% | ||||||||||||||||||||||||
Total SG&A |
$ | 26,663 | 7.1 | % | $ | 41,045 | 11.6 | % | (35.0 | )% | $ | 52,846 | 7.2 | % | $ | 67,185 | 9.8 | % | (21.3 | )% | ||||||||||||||||||||
23
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||||||||||||||||||||||||||
% of | % of | % | % of | % of | % | |||||||||||||||||||||||||||||||||||
$ | Revenue | $ | Revenue | Change | $ | Revenue | $ | Revenue | Change | |||||||||||||||||||||||||||||||
Animal Hospital |
$ | 46,845 | 16.1 | % | $ | 43,390 | 16.2 | % | 8.0 | % | $ | 80,237 | 14.3 | % | $ | 79,496 | 15.5 | % | 0.9 | % | ||||||||||||||||||||
Laboratory |
33,809 | 40.1 | % | 34,029 | 41.0 | % | (0.6 | )% | 63,892 | 39.0 | % | 64,402 | 40.0 | % | (0.8 | )% | ||||||||||||||||||||||||
Medical Technology |
1,204 | 7.4 | % | 929 | 6.4 | % | 29.6 | % | 2,106 | 6.0 | % | 2,205 | 7.3 | % | (4.5 | )% | ||||||||||||||||||||||||
Corporate |
(10,182 | ) | (25,448 | ) | (60.0 | )% | (20,090 | ) | (36,332 | ) | (44.7 | )% | ||||||||||||||||||||||||||||
Intercompany |
(1,567 | ) | (447 | ) | 250.6 | % | (2,530 | ) | (688 | ) | 267.7 | % | ||||||||||||||||||||||||||||
Total operating income |
$ | 70,109 | 18.6 | % | $ | 52,453 | 14.8 | % | 33.7 | % | $ | 123,615 | 16.9 | % | $ | 109,083 | 15.9 | % | 13.3 | % | ||||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Interest expense: |
||||||||||||||||
Senior term notes |
$ | 3,045 | $ | 2,326 | $ | 6,182 | $ | 4,575 | ||||||||
Interest rate hedging agreements |
- | - | - | 382 | ||||||||||||
Capital leases and other |
1,304 | 559 | 1,973 | 1,123 | ||||||||||||
Amortization of debt costs |
386 | 107 | 774 | 239 | ||||||||||||
4,735 | 2,992 | 8,929 | 6,319 | |||||||||||||
Interest income |
(160 | ) | (214 | ) | (335 | ) | (374 | ) | ||||||||
Total interest expense, net of interest income |
$ | 4,575 | $ | 2,778 | $ | 8,594 | $ | 5,945 | ||||||||
24
25
Six Months Ended | ||||||||
June 30, | ||||||||
2011 | 2010 | |||||||
Cash provided by (used in): |
||||||||
Operating activities |
$ | 115,620 | $ | 111,336 | ||||
Investing activities |
(42,491 | ) | (49,456 | ) (1) | ||||
Financing activities |
(14,625 | ) | (13,298 | ) (1) | ||||
Effect of currency exchange rate changes on cash and cash equivalents |
153 | (6 | ) | |||||
Increase in cash and cash equivalents |
58,657 | 48,576 | ||||||
Cash and cash equivalents at beginning of period |
97,126 | 145,181 | ||||||
Cash and cash equivalents at end of period |
$ | 155,783 | $ | 193,757 | ||||
(1) | To conform to the current year presentation we have reclassed prior year cash paid for partnership buyouts from the cash flows from investing to the financing cash flows. |
26
Six Months Ended | ||||||||||||
June 30, | ||||||||||||
Investing Cash Flows: | 2011 | 2010 | Variance | |||||||||
Acquisition of independent animal
hospitals and laboratories |
$ | (11,600 | ) | $ | (19,350 | ) | $ | 7,750 | (1) | |||
Other |
(204 | ) | (728 | ) | 524 | (2) | ||||||
Total cash used for acquisitions and related real estate |
(11,804 | ) | (20,078 | ) | 8,274 | |||||||
Property and equipment additions |
(28,434 | ) | (27,925 | ) | (509 | ) | ||||||
Real estate acquired with acquisitions |
(1,900 | ) | (1,300 | ) | (600 | ) (3) | ||||||
Proceeds from sale of assets |
140 | 9 | 131 | |||||||||
Other |
(493 | ) | (162 | ) | (331 | ) | ||||||
Net cash used in investing activities |
$ | (42,491 | ) | $ | (49,456 | ) | $ | 6,965 | ||||
(1) | The number of acquisitions will vary from year to year based upon the available pool of suitable candidates. A discussion of our acquisitions is provided above in our Executive Overview. | |
(2) | In conformance with the current year presentation we have reclassed prior year cash paid for partnership buyouts to the cash flows from financing. | |
(3) | The cash used to acquire property and equipment will vary from period to period based on upgrade requirements and expansion of our animal hospital and laboratory facilities. |
Six Months Ended | ||||||||||||
June 30, | ||||||||||||
Financing Cash Flows: | 2011 | 2010 | Variance | |||||||||
Repayment of debt |
$ | (14,164 | ) | $ | (12,859 | ) | $ | (1,305) | (1) | |||
Distributions to noncontrolling interest partners |
(1,141 | ) | (2,021 | ) | 880 | (2) | ||||||
Proceeds from issuance of common stock under stock option plans |
2,456 | 3,770 | (1,314 | ) (3) | ||||||||
Excess tax benefit from exercise of stock options |
906 | 331 | 575 | |||||||||
Stock repurchases |
(2,337 | ) | (2,253 | ) | (84 | ) (4) | ||||||
Other |
(345 | ) | (266 | ) | (79 | ) (5) | ||||||
Net cash used in financing activities |
$ | (14,625 | ) | $ | (13,298 | ) | $ | (1,327 | ) | |||
(1) | The cash used for repayment of debt increased $1.3 million. The scheduled principal payment on our senior term debt was $12.5 million for June 30, 2011 compared to $2.7 million for June 30, 2010; however, the repayment of debt for June 30, 2010 also includes $8.8 million for the payment of excess cash flows pursuant to our previous credit agreement, which was renegotiated in August 2010. Our current credit agreement does not require the payment of excess cash flows. | |
(2) | The distributions to noncontrolling interest partners represent cash payments to noncontrolling interest partners for their portion of the partnerships excess cash. | |
(3) | The number of stock option exercises has decreased in comparison to the prior year as the prior year amount was impacted by the expiration of certain stock option grants. | |
(4) | The stock repurchases for the six months ended June 30, 2011 and June 30, 2010 represent tax payments made on behalf of employees in lieu of stock certificates due to the employee on the vesting date. |
27
(5) | In conformance with the current year presentation we have reclassed prior year cash paid for partnership buyouts from the cash flows from investing to the financing cash flows. |
28
31.1
|
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2
|
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
32.1
|
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
101.INS
|
XBRL Instance Document* | |
101.SCH
|
XBRL Taxonomy Extension Schema Document* | |
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase* | |
101.DEF
|
XBRL Taxonomy Definition Linkbase* | |
101.LAB
|
XBRL Taxonomy Extension Label Linkbase* | |
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase* |
* Furnished, not filed. |
29
Date: August 5, 2011 | By: | /s/ Tomas W. Fuller | ||
Tomas W. Fuller | ||||
Chief Financial Officer |
30
Exhibit No. | Description | |
31.1
|
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2
|
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
32.1
|
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
31
1. | I have reviewed this quarterly report on Form 10-Q of VCA Antech, Inc.; | |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
4. | The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the Audit Committee of the registrants Board of Directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
/s/ Robert L. Antin
Robert L. Antin |
||
Chief Executive Officer |
1. | I have reviewed this quarterly report on Form 10-Q of VCA Antech, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | ||
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | ||
c. | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | ||
d. | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the Audit Committee of the registrants Board of Directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and | ||
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
/s/ Tomas W. Fuller Tomas W. Fuller |
||
Chief Financial Officer |
(i) | the Report fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and | ||
(ii) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Issuer. |
/s/ Robert L. Antin | ||||
Robert L. Antin | ||||
Chief Executive Officer | ||||
/s/ Tomas W. Fuller | ||||
Tomas W. Fuller | ||||
Chief Financial Officer | ||||
Condensed, Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)
In Thousands, except Per Share data |
Jun. 30, 2011
|
Dec. 31, 2010
|
---|---|---|
Current assets: | ||
Allowance for uncollectible accounts | $ 13,197 | $ 13,801 |
Accumulated depreciation and amortization on property and equipment | $ 218,735 | $ 198,157 |
Liabilities and Equity | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 11,000 | 11,000 |
Preferred stock, shares outstanding | 0 | 0 |
VCA Antech, Inc. stockholders' equity: | ||
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 175,000 | 175,000 |
Common stock, shares outstanding | 86,595 | 86,179 |
Condensed, Consolidated Income Statements (Unaudited) (USD $)
In Thousands, except Per Share data |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2011
|
Jun. 30, 2010
|
|
Condensed, Consolidated Income Statements [Abstract] | ||||
Revenue | $ 376,105 | $ 353,919 | $ 731,228 | $ 684,653 |
Direct costs | 279,273 | 260,435 | 554,618 | 508,374 |
Gross profit | 96,832 | 93,484 | 176,610 | 176,279 |
Selling, general and administrative expense | 26,663 | 41,045 | 52,846 | 67,185 |
Net loss (gain) on sale of assets | 60 | (14) | 149 | 11 |
Operating income | 70,109 | 52,453 | 123,615 | 109,083 |
Interest expense, net | 4,575 | 2,778 | 8,594 | 5,945 |
Other income | (67) | (335) | (9) | (310) |
Income before provision for income taxes | 65,601 | 50,010 | 115,030 | 103,448 |
Provision for income taxes | 25,536 | 19,493 | 44,469 | 39,999 |
Net income | 40,065 | 30,517 | 70,561 | 63,449 |
Net income attributable to noncontrolling interests | 453 | 1,113 | 2,110 | 2,110 |
Net income attributable to VCA Antech, Inc. | $ 39,612 | $ 29,404 | $ 68,451 | $ 61,339 |
Basic earnings per share | $ 0.46 | $ 0.34 | $ 0.79 | $ 0.71 |
Diluted earnings per share | $ 0.45 | $ 0.34 | $ 0.78 | $ 0.70 |
Weighted-average shares outstanding for basic earnings per share | 86,535 | 86,041 | 86,445 | 85,933 |
Weighted-average shares outstanding for diluted earnings per share | 87,304 | 87,178 | 87,303 | 87,069 |
Other Accrued Liabilities (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Accrued Liabilities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Accrued Liabilities |
|
Document and Entity Information (USD $)
In Billions, except Share data |
6 Months Ended | ||
---|---|---|---|
Jun. 30, 2011
|
Aug. 01, 2011
|
Jun. 30, 2010
|
|
Document and Entity Information [Abstract] | |||
Entity Registrant Name | VCA ANTECH INC | ||
Entity Central Index Key | 0000817366 | ||
Document Type | 10-Q | ||
Document Period End Date | Jun. 30, 2011 | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2011 | ||
Document Fiscal Period Focus | Q2 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Public Float | $ 2.1 | ||
Entity Common Stock, Shares Outstanding | 86,595,392 |
Calculation of Earnings Per Share (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Calculation of Earnings per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Calculation of Basic and Diluted Earnings per Share |
|
"+ text.join( "
\n" ) +"
" + text[p] + "
\n"; } } }else{ formatted = '' + raw + '
'; } html = ''+ "\n"+''+ "\n"+''+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+' | '+ "\n"+'
'+ "\n"+' | '+ "\n"+' '+ "\n"+'
'+ "\n"+' | '+ "\n"+' '+ "\n"+'
Fair Value Measurements
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements |
5. Fair Value Measurements
Fair Value of Financial Instruments
The FASB accounting guidance requires disclosure of fair value information about financial
instruments, whether or not recognized in the accompanying condensed, consolidated balance sheets.
Fair value as defined by the guidance is the price that would be received to sell an asset or paid
to transfer a liability in an orderly transaction between market participants at the measurement
date. The fair value estimates of financial instruments are not necessarily indicative of the
amounts we might pay or receive in actual market transactions. The use of different market
assumptions and/or estimation methodologies may have a material effect on the estimated fair value
amounts.
Cash and Cash Equivalents. These balances include cash and cash equivalents with maturities
of less than three months. The carrying amount approximates fair value due to the short-term
maturities of these instruments.
Receivables, Less Allowance for Doubtful Accounts, Accounts Payable and Certain Other Accrued
Liabilities. Due to their short-term nature, fair value approximates carrying value.
Long-Term Debt. The fair value of debt at June 30, 2011 and December 31, 2010 is based upon
the ask price quoted from an external source, which is considered a Level 2 input.
The
following table reflects the carrying value and fair value of our
variable-rate long-term debt (in
thousands):
At June 30, 2011 and December 31, 2010, we did not have any applicable nonrecurring
measurements of nonfinancial assets and nonfinancial liabilities.
|
Comprehensive Income (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive Income [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of comprehensive income |
|
Subsequent Events (Details) (USD $)
|
6 Months Ended | |||
---|---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jul. 10, 2011
MediMedia [Member]
|
Jul. 11, 2011
BrightHeart [Member]
|
|
Business Acquisition [Line Items] | ||||
Cash paid for acquisitions | $ 11,445,000 | $ 19,350,000 | $ 146,000,000 | $ 50,000,000 |
Subsequent Events (Textuals) [Abstract] | ||||
Incremental financing under senior credit facility | $ 100,000,000 |
Share-Based Compensation (Tables)
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of stock option activity |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of nonvested stock activity |
|
Commitments and Contingencies
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Commitments and Contingencies [Abstract] | |
Commitments and Contingencies |
10. Commitments and Contingencies
We have certain commitments, including operating leases and acquisition agreements. These
items are discussed in detail in our consolidated financial statements and notes thereto included
in our 2010 Annual Report on Form 10-K. We also have contingencies as follows:
a. Earn-Out Payments
We have contractual arrangements in connection with certain acquisitions that were accounted
for under previous business combinations accounting guidance, whereby additional cash may be paid
to former owners of acquired companies upon attainment of specified financial criteria as set forth
in the respective agreements. The amount to be paid cannot be determined until the earn-out
periods expire and the attainment of criteria is established. If the specified financial criteria
are attained we will be obligated to pay an additional $972,000. Under the current business
combination accounting guidance contingent consideration, such as earn-out liabilities, are
recognized as part of the consideration transferred on the acquisition date and a corresponding
liability is recorded based on the fair value of the liability if the fair value is known or
determinable. The changes in fair value are recognized in earnings where applicable at each
reporting period.
b. Other Contingencies
We have certain contingent liabilities resulting from litigation and claims incident to the
ordinary course of our business. We believe that the probable resolution of such contingencies
will not have a material adverse effect on our consolidated financial position, results of
operations or cash flows.
|
Nature of Operations
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Nature of Operations and Basis of Presentation [Abstract] | |
Nature of Operations |
1. Nature of Operations
Our company, VCA Antech, Inc. (“VCA”) is a Delaware corporation formed in 1986 and is based in
Los Angeles, California. We are an animal healthcare company with three strategic segments: animal
hospitals (“Animal Hospital”), veterinary diagnostic laboratories (“Laboratory”) and veterinary
medical technology (“Medical Technology”).
Our animal hospitals offer a full range of general medical and surgical services for companion
animals. Our animal hospitals treat diseases and injuries, provide pharmaceutical products and
perform a variety of pet-wellness programs, including health examinations, diagnostic testing,
vaccinations, spaying, neutering and dental care. At June 30, 2011, we operated 530 animal
hospitals throughout 41 states.
We operate a full-service veterinary diagnostic laboratory network serving all 50 states and
certain areas in Canada. Our laboratory network provides sophisticated testing and consulting
services used by veterinarians in the detection, diagnosis, evaluation, monitoring, treatment and
prevention of diseases and other conditions affecting animals. At June 30, 2011, we operated 52
laboratories of various sizes located strategically throughout the United States and Canada.
Our Medical Technology segment sells digital radiography and ultrasound imaging equipment,
provides education and training on the use of that equipment, provides consulting and mobile
imaging services, and sells software and ancillary services to the veterinary market.
|
Calculation of Earnings per Share
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Calculation of Earnings per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Calculation of Earnings per Share |
7. Calculation of Earnings per Share
Basic earnings per share is calculated by dividing net income by the weighted-average number
of shares outstanding during the period. Diluted earnings per share is calculated by dividing net
income attributable to VCA Antech, Inc. by the weighted-average number of common shares
outstanding, after giving effect to all dilutive potential common shares outstanding during the
period. Basic and diluted earnings per share were calculated as follows (in thousands, except per
share amounts):
For the three months ended June 30, 2011 and 2010, potential common shares of 1,139,567 and
4,200, respectively, were excluded from the computation of diluted earnings per share because their
inclusion would have had an antidilutive effect. For the six months ended June 30, 2011 and 2010,
potential common shares of 40,067 and 12,264, respectively, were excluded from the computation of
diluted earnings per share because their inclusion would have had an antidilutive effect.
|
Recent Accounting Pronouncements
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Recent Accounting Pronouncements [Abstract] | |
Recent Accounting Pronouncements |
12. Recent Accounting Pronouncements
In May 2011, the Financial Accounting Standards Board (FASB) amended the accounting guidance
for Fair Value Measurement to achieve common fair value measurement and disclosure requirements in
U.S. GAAP and IFRS (International Financial Reporting Standards). The amendments explain how to
measure fair value, however they do not require additional fair value measurements and are not
intended to establish valuation standards or affect valuation practices outside of financial
reporting. The amendments are to be applied prospectively and are effective during interim and
annual periods beginning after December 15, 2011. Early application by public entities is not
permitted. The adoption of this new guidance is not expected to have a significant impact our
consolidated financial statements.
In June 2011, the FASB finalized the accounting guidance for the Presentation of Comprehensive
Income. The objective of the new guidance is to improve the comparability, consistency, and
transparency of financial reporting, to increase the prominence of the items reported in other
comprehensive income and to facilitate convergence of GAAP and IFRS. The guidance eliminates the
option to present components of other comprehensive income as part of the statement of changes in
stockholder’s equity and requires that all nonowner changes in stockholders’ equity be presented
either in a single continuous statement of comprehensive income or in two separate but consecutive
statements. In both choices, an entity is required to present each component of net income along
with total net income, each component of other comprehensive income along with a total for other
comprehensive income, and a total amount for comprehensive income. The statement of other
comprehensive income should immediately follow the statement of net income. Regardless of which
option is chosen it is required that reclassification adjustments for items that are reclassified
from other comprehensive income to net income be presented on the face of the financial statements.
The new guidance does not change the following: the items that must be reported in other
comprehensive income; when an item of other comprehensive income must be reclassified to net
income; the option for an entity to present components of other comprehensive income either net of
related tax effects or before related tax effects; and does not affect how earnings per share is
calculated or presented.
The guidance is effective for fiscal years, and interim periods within those years, beginning
after December 15, 2011 and should be applied retrospectively. Early adoption is permitted. The
adoption of the new disclosure requirements will have no effect on our consolidated financial
statements other than the changes to presentation outlined.
|
Comprehensive Income
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive Income [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive Income |
8. Comprehensive Income
Total comprehensive income consists of net income and the other comprehensive income during
the three and six months ended June 30, 2011 and 2010. The following table provides a summary of
comprehensive income (in thousands):
|
Share-Based Compensation
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation |
6. Share-Based Compensation
Stock Option Activity
A summary of our stock option activity for the six months ended June 30, 2011 is as follows
(in thousands):
There were no stock options granted during the six months ended June 30, 2011. The aggregate
intrinsic value of our stock options exercised during the three and six months ended June 30, 2011
was $2.3 million and $3.0 million, respectively, and the actual tax benefit realized on options
exercised during these periods was $888,000 and $1.2 million, respectively.
At June 30, 2011 there was $907,000 of total unrecognized compensation cost related to our
stock options. This cost is expected to be recognized over a weighted-average period of one year.
The compensation cost that has been charged against income for stock options for the three
months ended June 30, 2011 and 2010 was $347,000 and $1.4 million, respectively. The corresponding
income tax benefit recognized was $136,000 and $528,000 for the three months ended June 30, 2011
and 2010, respectively.
The compensation cost that has been charged against income for stock options for the six
months ended June 30, 2011 and 2010 was $694,000 and $1.8 million, respectively. The corresponding
income tax benefit recognized was $271,000 and $711,000 for the six months ended June 30, 2011 and
2010, respectively.
Nonvested Stock Activity
During the six months ended June 30, 2011 we granted 1,148,046 shares of nonvested common
stock, 1,130,000 of which were granted to certain of our executives and contain performance
conditions. The performance-based awards provide that the number of shares that will ultimately
vest will be between 0% and 100% of the total granted based on the attainment of performance
targets. Assuming continued service through each vesting date, these awards will vest in four
equal annual installments beginning June 2012 through June 2015.
Total compensation cost charged against income related to nonvested stock awards was $1.1
million and $2.4 million for the three months ended June 30, 2011 and 2010, respectively. The
corresponding income tax benefit recognized in the income statement was $436,000 and $939,000 for
the three months ended June 30, 2011 and 2010, respectively.
Total compensation cost charged against income related to nonvested stock awards was $1.8
million and $4.0 million for the six months ended June 30, 2011 and 2010, respectively. The
corresponding income tax benefit recognized in the income statement was $717,000 and $1.6 million
for the six months ended June 30, 2011 and 2010, respectively.
At June 30, 2011, there was $28.3 million of unrecognized compensation cost related to these
nonvested shares, which will be recognized over a weighted-average period of 3.7 years. A summary
of our nonvested stock activity for the six months ended June 30, 2011 is as follows:
|
Condensed, Consolidated Statements of Equity (Unaudited) (Parenthetical) (USD $)
In Thousands |
6 Months Ended | |
---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
|
Redeemable noncontrolling interests | $ 830 | $ 382 |
Mandatorily redeemable noncontrolling interests | 227 | 225 |
Retained Earnings
|
||
Redeemable noncontrolling interests | 830 | 382 |
Mandatorily redeemable noncontrolling interests | 227 | 225 |
Noncontrolling Interests
|
||
Redeemable noncontrolling interests | 830 | 382 |
Mandatorily redeemable noncontrolling interests | $ 227 | $ 225 |
Basis of Presentation
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Nature of Operations and Basis of Presentation [Abstract] | |
Basis of Presentation |
2. Basis of Presentation
Our accompanying unaudited, condensed, consolidated financial statements have been prepared in
accordance with generally accepted accounting principles in the United States (“GAAP”) for interim
financial information and in accordance with the rules and regulations of the United States
Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the
information and notes required by GAAP for annual financial statements as permitted under
applicable rules and regulations. In the opinion of management, all normal recurring adjustments
considered necessary for a fair presentation have been included. The results of operations for the
three and six months ended June 30, 2011 are not necessarily indicative of the results to be
expected for the full year ending December 31, 2011. For further information, refer to our
consolidated financial statements and notes thereto included in our 2010 Annual Report on Form 10-K.
Certain reclassifications have been made herein to 2010 amounts to conform to the current year
presentation. In our condensed, consolidated balance sheet as of December 31, 2010,
we corrected certain errors in presentation by reclassifying $5.8 million to temporary equity
(mezzanine) from noncontrolling interests included in permanent equity related to partnership
agreements that contain certain terms which may require us to purchase the partners’ equity based
upon certain contingencies. As these agreements do not contain a mandatory redemption clause, the
balances are now correctly classified in temporary equity (mezzanine). Additionally, we
reclassified $506,000 from noncontrolling interests in permanent equity to other liabilities
related to our mandatorily redeemable partnership interests. The change in classification of our
redeemable noncontrolling interests also impacts our condensed, consolidated statement of equity
for the six months ended June 30, 2010, accordingly, certain amounts related to redeemable
noncontrolling interests were reclassified from the noncontrolling interests column in the
statement, see Note 11, Noncontrolling Interests, which presents a summary of the amounts
reclassified.
During the quarter ended March 31, 2011, we corrected an error related to our deferred revenue
and related deferred cost for certain equipment sales governed by recently revised accounting
guidance related to multiple element arrangements. The correction resulted in the recognition of
$4.0 million of previously deferred revenue and $3.8 million of previously deferred costs in our
Medical Technology segment
The preparation of our condensed, consolidated financial statements in accordance with GAAP
requires management to make estimates and assumptions that affect the amounts reported in our
condensed, consolidated financial statements and notes thereto. Actual results could differ from
those estimates.
|
Commitments and Contingencies (Details) (USD $)
|
Jun. 30, 2011
|
---|---|
Commitments and Contingencies (Textuals) [Abstract] | |
Additional payment for specified financial criteria | $ 972,000 |
Basis of Presentation (Details) (USD $)
|
3 Months Ended | 6 Months Ended | 12 Months Ended |
---|---|---|---|
Mar. 31, 2011
|
Jun. 30, 2011
|
Dec. 31, 2010
|
|
Basis of Presentation (Textuals) [Abstract] | |||
Reclassification Adjustment | $ 506,000 | $ 5,800,000 | |
Recognition of deferred revenue | 4,000,000 | ||
Recognition of deferred cost | $ 3,800,000 |
Goodwill and Other Intangible Assets
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Other Intangible Assets [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Other Intangible Assets |
3. Goodwill and Other Intangible Assets
Goodwill
The
following table presents the changes in the carrying amount of our
goodwill for the six
months ended June 30, 2011 (in thousands):
We had no accumulated impairment losses as of June 30, 2011.
Other Intangible Assets
Our amortizable intangible assets at June 30, 2011 and December 31, 2010 are as follows (in thousands):
The following table summarizes our aggregate amortization expense related to other intangible
assets (in thousands):
The estimated amortization expense related to intangible assets for the remainder of 2011 and
each of the succeeding years thereafter as of June 30, 2011 is as follows (in thousands):
|
Noncontrolling Interests (Details Textuals) (USD $)
In Millions, unless otherwise specified |
Jun. 30, 2011
|
Dec. 31, 2010
|
---|---|---|
Noncontrolling Interests (Textuals) [Abstract] | ||
Percentage of ownership interest in partnership | 50.10% | |
Mandatorily Redeemable Noncontrolling Interests included in other liabilities | $ 3.1 | $ 1.7 |
Redeemable Noncontrolling Interest [Member]
|
||
Noncontrolling Interests (Textuals) [Abstract] | ||
Redeemable Noncontrolling Interests | $ 6.3 | $ 5.8 |
Lines of Business (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lines of Business [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lines of Business |
|
Other Accrued Liabilities (Details) (USD $)
In Thousands |
Jun. 30, 2011
|
Dec. 31, 2010
|
---|---|---|
Other accrued liabilities | ||
Deferred revenue | $ 6,914 | $ 8,617 |
Accrued health insurance | 5,268 | 4,970 |
Deferred rent | 3,780 | 3,456 |
Accrued consulting fees | 2,760 | 2,760 |
Holdbacks and earnouts | 2,600 | 2,447 |
Customer deposits | 1,939 | 2,966 |
Accrued lab service rebates | 132 | 2,535 |
Other | 18,253 | 18,018 |
Other accrued liabilities | $ 41,646 | $ 45,769 |
Noncontrolling Interests (Details) (USD $)
In Thousands |
6 Months Ended | |
---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
|
Summary of redeemable noncontrolling interests | ||
Redeemable noncontrolling interests, Beginning balance | $ 5,799 | $ 4,369 |
Non controlling interest | 428 | 382 |
Redemption value change | 402 | |
Redeemable noncontrolling interests | 830 | 382 |
Redeemable noncontrolling interests, Ending balance | 6,257 | 4,915 |
Redeemable Noncontrolling Interest [Member]
|
||
Summary of redeemable noncontrolling interests | ||
Redeemable noncontrolling interests | 830 | 382 |
Formation of noncontrolling interests | 450 | |
Distribution to noncontrolling interests | $ (372) | $ (286) |
Nature of Operations (Details)
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Nature of Operations (Textuals) [Abstract] | |
Number of hospitals operated | 530 |
Number of states in which hospitals are operated | 41 |
Number of states in which the company operate a full-service veterinary diagnostic laboratory network | 50 |
Number of laboratories operated | 52 |
Noncontrolling interests
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noncontrolling Interests [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non controlling interests |
11. Noncontrolling Interests
We own some of our animal hospitals in partnerships with noncontrolling interest holders. We
consolidate our partnerships in our consolidated financial statements because our ownership
interest in these partnerships is equal to or greater than 50.1% and we control these entities. We
record noncontrolling interest in income of subsidiaries equal to our partners’ percentage
ownership of the partnerships’ income. We also record changes in the redemption value of our
mandatorily redeemable and redeemable noncontrolling interests in net income attributable to
noncontrolling interests in our condensed, consolidated income statements. We reflect our
noncontrolling partners’ cumulative share in the equity of the respective partnerships as either
noncontrolling interests in equity, mandatorily redeemable noncontrolling interests in other
liabilities or redeemable noncontrolling interests in temporary equity (mezzanine).
a. Mandatorily Redeemable Noncontrolling Interests
The terms of some of our partnership agreements require us to purchase the partner’s equity in
the partnership in the event of the partner’s death. We report these redeemable noncontrolling
interests at their estimated redemption value and classify them as liabilities due to the certainty
of the related event. We recognize changes in the obligation in net income attributable to
noncontrolling interests. At June 30, 2011 and December 31, 2010, these liabilities were $3.1
million and $1.7 million, respectively, and are included in other liabilities in our consolidated
balance sheets.
b. Redeemable Noncontrolling Interests
We also enter into partnership agreements whereby the minority partner is issued certain “put”
rights. These rights are normally exercisable at the sole discretion of the minority partner. We
report these redeemable noncontrolling interests at their estimated redemption value and classify
them in temporary equity (mezzanine). We recognize changes in the obligation in net income
attributable to noncontrolling interests. At June 30, 2011 and December 31, 2010, balances in
temporary equity related to these types of arrangements were $6.3 million and $5.8 million,
respectively.
The following table provides a summary of redeemable noncontrolling interests (in thousands):
|
Other Accrued Liabilities
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Accrued Liabilities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Accrued Liabilities |
4. Other Accrued Liabilities
Other accrued liabilities consisted of the following (in thousands):
|
Lines of Business (Policies)
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Lines of Business [Abstract] | |
Segment Reporting |
Our reportable segments are Animal Hospital, Laboratory and Medical Technology. These
segments are strategic business units that have different services, products and/or functions. The
segments are managed separately because each is a distinct and different business venture with
unique challenges, risks and rewards. Our Animal Hospital segment provides veterinary services for
companion animals and sells related retail and pharmaceutical products. Our Laboratory segment
provides diagnostic laboratory testing services for veterinarians, both associated with our animal
hospitals and those independent of us. Our Medical Technology segment sells digital radiography
and ultrasound imaging equipment, related computer hardware, software and ancillary services to the
veterinary market. We also operate a corporate office that provides general and administrative
support services for our other segments.
The accounting policies of our segments are essentially the same as those described in the
summary of significant accounting policies included in our 2010 Annual Report on Form 10-K. We
evaluate the performance of our segments based on gross profit and operating income. For purposes
of reviewing the operating performance of our segments all intercompany sales and purchases are
generally accounted for as if they were transactions with independent third parties at current
market prices.
|
Fair Value Measurement |
In May 2011, the Financial Accounting Standards Board (FASB) amended the accounting guidance
for Fair Value Measurement to achieve common fair value measurement and disclosure requirements in
U.S. GAAP and IFRS (International Financial Reporting Standards). The amendments explain how to
measure fair value, however they do not require additional fair value measurements and are not
intended to establish valuation standards or affect valuation practices outside of financial
reporting. The amendments are to be applied prospectively and are effective during interim and
annual periods beginning after December 15, 2011. Early application by public entities is not
permitted. The adoption of this new guidance is not expected to have a significant impact our
consolidated financial statements.
|
Presentation of Comprehensive Income |
In June 2011, the FASB finalized the accounting guidance for the Presentation of Comprehensive
Income. The objective of the new guidance is to improve the comparability, consistency, and
transparency of financial reporting, to increase the prominence of the items reported in other
comprehensive income and to facilitate convergence of GAAP and IFRS. The guidance eliminates the
option to present components of other comprehensive income as part of the statement of changes in
stockholder’s equity and requires that all nonowner changes in stockholders’ equity be presented
either in a single continuous statement of comprehensive income or in two separate but consecutive
statements. In both choices, an entity is required to present each component of net income along
with total net income, each component of other comprehensive income along with a total for other
comprehensive income, and a total amount for comprehensive income. The statement of other
comprehensive income should immediately follow the statement of net income. Regardless of which
option is chosen it is required that reclassification adjustments for items that are reclassified
from other comprehensive income to net income be presented on the face of the financial statements.
The new guidance does not change the following: the items that must be reported in other
comprehensive income; when an item of other comprehensive income must be reclassified to net
income; the option for an entity to present components of other comprehensive income either net of
related tax effects or before related tax effects; and does not affect how earnings per share is
calculated or presented.
The guidance is effective for fiscal years, and interim periods within those years, beginning
after December 15, 2011 and should be applied retrospectively. Early adoption is permitted. The
adoption of the new disclosure requirements will have no effect on our consolidated financial
statements other than the changes to presentation outlined.
|
Lines of Business (Details) (USD $)
In Thousands |
3 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2011
|
Jun. 30, 2010
|
Dec. 31, 2010
|
|
Lines of Business | |||||
External revenue | $ 376,105 | $ 353,919 | $ 731,228 | $ 684,653 | |
Total revenue | 376,105 | 353,919 | 731,228 | 684,653 | |
Direct costs | 279,273 | 260,435 | 554,618 | 508,374 | |
Gross profit | 96,832 | 93,484 | 176,610 | 176,279 | |
Selling, general and administrative expense | 26,663 | 41,045 | 52,846 | 67,185 | |
Net loss (gain) on sale of assets | 60 | (14) | 149 | 11 | |
Operating income (loss) | 70,109 | 52,453 | 123,615 | 109,083 | |
Depreciation and amortization | 13,076 | 10,999 | 26,456 | 21,706 | |
Capital expenditures | 16,400 | 11,876 | 28,434 | 27,925 | |
Total assets | 1,843,412 | 1,843,412 | 1,766,422 | ||
Animal Hospital [Member]
|
|||||
Lines of Business | |||||
External revenue | 291,332 | 267,595 | 561,273 | 514,263 | |
Total revenue | 291,332 | 267,595 | 561,273 | 514,263 | |
Direct costs | 238,392 | 218,567 | 468,780 | 423,558 | |
Gross profit | 52,940 | 49,028 | 92,493 | 90,705 | |
Selling, general and administrative expense | 6,044 | 5,673 | 12,127 | 11,260 | |
Net loss (gain) on sale of assets | 51 | (35) | 129 | (51) | |
Operating income (loss) | 46,845 | 43,390 | 80,237 | 79,496 | |
Depreciation and amortization | 9,533 | 7,630 | 19,406 | 14,982 | |
Capital expenditures | 13,236 | 9,849 | 22,771 | 22,977 | |
Total assets | 1,338,034 | 1,338,034 | 1,320,619 | ||
Laboratory [Member]
|
|||||
Lines of Business | |||||
External revenue | 72,955 | 73,259 | 142,051 | 142,659 | |
Intercompany revenue | 11,430 | 9,713 | 21,883 | 18,493 | |
Total revenue | 84,385 | 82,972 | 163,934 | 161,152 | |
Direct costs | 43,716 | 42,416 | 86,535 | 84,068 | |
Gross profit | 40,669 | 40,556 | 77,399 | 77,084 | |
Selling, general and administrative expense | 6,853 | 6,527 | 13,489 | 12,681 | |
Net loss (gain) on sale of assets | 7 | 18 | 1 | ||
Operating income (loss) | 33,809 | 34,029 | 63,892 | 64,402 | |
Depreciation and amortization | 2,508 | 2,396 | 4,979 | 4,809 | |
Capital expenditures | 1,728 | 1,506 | 2,964 | 2,338 | |
Total assets | 228,571 | 228,571 | 215,483 | ||
Medical Technology [Member]
|
|||||
Lines of Business | |||||
External revenue | 11,818 | 13,065 | 27,904 | 27,731 | |
Intercompany revenue | 4,391 | 1,537 | 7,401 | 2,668 | |
Total revenue | 16,209 | 14,602 | 35,305 | 30,399 | |
Direct costs | 11,419 | 10,255 | 26,057 | 21,221 | |
Gross profit | 4,790 | 4,347 | 9,248 | 9,178 | |
Selling, general and administrative expense | 3,584 | 3,404 | 7,140 | 6,919 | |
Net loss (gain) on sale of assets | 2 | 14 | 2 | 54 | |
Operating income (loss) | 1,204 | 929 | 2,106 | 2,205 | |
Depreciation and amortization | 668 | 605 | 1,325 | 1,206 | |
Capital expenditures | 258 | 124 | 1,017 | 206 | |
Total assets | 64,851 | 64,851 | 69,082 | ||
Corporate [Member]
|
|||||
Lines of Business | |||||
Selling, general and administrative expense | 10,182 | 25,441 | 20,090 | 36,325 | |
Net loss (gain) on sale of assets | 7 | 7 | |||
Operating income (loss) | (10,182) | (25,448) | (20,090) | (36,332) | |
Depreciation and amortization | 685 | 618 | 1,365 | 1,199 | |
Capital expenditures | 1,627 | 858 | 2,585 | 3,185 | |
Total assets | 229,608 | 229,608 | 175,297 | ||
Intercompany Eliminations [Member]
|
|||||
Lines of Business | |||||
Intercompany revenue | (15,821) | (11,250) | (29,284) | (21,161) | |
Total revenue | (15,821) | (11,250) | (29,284) | (21,161) | |
Direct costs | (14,254) | (10,803) | (26,754) | (20,473) | |
Gross profit | (1,567) | (447) | (2,530) | (688) | |
Operating income (loss) | (1,567) | (447) | (2,530) | (688) | |
Depreciation and amortization | (318) | (250) | (619) | (490) | |
Capital expenditures | (449) | (461) | (903) | (781) | |
Total assets | $ (17,652) | $ (17,652) | $ (14,059) |
Noncontrolling Interests (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noncontrolling Interests [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of redeemable noncontrolling interests |
|
6/\CJ],F0!DY5`,1/.C@Q;B7*"\\S
MZM2GHP>U: -;)5"\:<<@MJR<%?F#59EAL_)J]>#-88NQJSIM5R4=M Z0$AI"/;(FI%?!#2/7BWIL0Z@BB$"8/S^^'XJT;
M)B;C?\4J"GP"-)BCK]). MR^LS13_[2Q&2/F(Z9\E9`E'4]I'1SL4?5/_
MU?_>,>TG-,YL>SY"7$<_/G,GHR?RSOI>[JSGDS$Y8FW";F%WLC^A5/'#230G
M!\72V+];9E%.&BE_7%TJEW@<)C.@O`\G?6Q'M#HCH;O`@@->$MJ.6LT%!ON1
M]Z&IM1Q@F"-4"C!2"X'.?GJP\7HM8M*5T],EDA')R.A')%>+=."%?RI?%]X$
ME==G06:X;"?;#;UOW<,<6177>WDI-_9)YU&H)+0V5HG66]>OY222[;ANUVP2
M]1#IZ>K^"48WZT:<.MMN.RE'9B_`&IA2U1@P'&I%J<$.TS@HI29P=3[K-.NF
MT?7]/9JDY#+'*=GU]A^1LHA2W,;W@LTU2ZY3LAW?[49;IXP:1Y`B.RA1!NW`
MU7IE& U5EHP]+A
M+HYW^]O-NFX,Q&!62USW=_UFF?@A2I++2;8#@!6+^+ #S\ W!"X!D-C_-$O(#XZ[X
MJ:DY=`8YAZHY)E+)P(+8#+=@37*JHX4HD8P[U$@.7`,:.=>-U"QCN10=O*BR
MX&20<$N[)&I[5)IV\HYQ1I6S:8AD=[Y=I4JD`B.*\RVKQB*GJJH+F-+:O7@I
M4;CE!6CU-LX[F[,-SI/W[R3?G^?SMT-WGJ";T/$.O/4:)\0D_*EVCNA3\"^@5(4.R7$B/%*\J>QJX57EVDORCYPIV=]=86Z69"
M!*H72HD56D*^P0Q5P-U)D7:T6`4IZQG5\-._D#+S'I$R07'JX9&:K.D'Y,QW
ML)R2T]_1ZAQX@+P$9;QYD_\N_4P#%.\A1H@^=J':3LTS_PG+)#2
MGWM8ICV$*"WXQJYT[-\M:>H*LTL[J'LT'_
Y&-]\6,W
M-5_$Z.PLFZU>>38?NN<+6&T7T#=WTQ)ZS,Y.MOS*)$_A9O_Q\.`>!"*I.SH#
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M=WVU:;3UU2;O5>$K?NSD@I:L
/@NVQHRV]8*:H?#&H\EBB.&H]C2B4BD\K`V_J/AJT4^X52.I
'^#.(&J>Z&LX5T1?)SE,?0^H1?WR99^G#"
M#LM;LJ;WI0XL[`-.56]`3SJ^S'.X7(;-VNE+HR3!\G.4KX5%+2Z>:;Z*"_XZ
MN#?88I':_+Z9VES[#`3HZ.WDIPC_UD+:;P@\K+^W(.*+KU5>?Z6P"Z/K)9MI
MT0.5?Z$W>;QJFS[>I*CX()(1]5=*."M!Q1DS3]!<);VR!6Z
MQ"6"P%;^<(TV10/'U&2&\G;LK[CR%B2=H&L(^7P&)WAX]X1?R<0V7+#[EG)Y
MX3__RC+%#!3O5#G4ALK5^\7!2%P:@*ES-VFDOV1U1JBK-Y:I+U7U0U;=FVX,
M`CJ>Y7&6BT1MMW251$41;^+541$SDY>975\DES(78)7_V!!$WJZV;2$T4T=`
MWEO1D1SWU(KMX63!&(;)`<:8XMYQFN5Q^:*VMLKC_))-K?.X$.=C4/7^L,"_
MB))0;1MJ'U_!*#'N35AUE?+)/Q&XT+DG_IOUO.6'ZJ.Q^A2!;YC]D%2!/Y
M19R:ZZ$$IQ,##UI3I"U2,??@\Z%."=/.__/H#XMKYAJMO!`<1,KTPS*3=<7QSSTIQB0^(J2;+=SC&41@G]
M8T&8BV<0^S#9GN8[]9G4%WD9TK@'81Q]W#G*;?.EB*E^NNG*FFDVK1F]'!>:
M3OP$@\DQXQM'.=Z/;O8];K)#C&LJ_SL@G7)!,,4H>@M0'F4W,?19;M4#??EH
M\>JGI[9JI#8:PGKV#I!<1;F1=V"U4/S^437TTU1;;N'QK#CL67%4![W4K/PE
M1^N?;V&:.1^ZOWQ4!9W4+%7AZ`4O"'CQ9X;AKF4NT(S]^Z47'3K4TQ>2%QX$
MZDL^5ZO7#$;/KRAZ!`GF,--O=/#O?WL_PK-"S^Y#=,<(O5T.1`U&Q\]XB;2Z
MPAWT!&E^^@7KRV$)?3Q<%`GX&]UIC"A)\]-')3D0H7LWO'0LTMQ)P$L4SP$T
MI2>,KQ]5Y7"T[AW1?FG:(KZO#,N_INT\QF#@6'2%06MM47-W',#R9&PX%*EI
M>XZWC.I9@!E-Z@3KJ&36L$%;79L7["BP2PV583MJHBV
JSR`"L1=B.9T&*QA!0A$2+^-W9I:=
M:#^?93%QM7EW+4\%)FN4P+QLX!33C%D[I&.\_0SO0*!_T^Q/.9\CL""-B?:J
M`JPI_+L&1(B)-5*&*%EQ7=8H^]G(!%M;/VC+E)2KC>-1NX9^:>@]7'/3VW"?
M[.?I
=,VP&7\RH'0XF';P-:Y6^GR51O''/CJ(`41*KV)D]T_=2.U.-QA84%D
MV,9GSFG&W?;I=MBE7:V6PN)CA^Y`=:[5V+4<7,KJ2HT]J4,HB]`EIN(W'(3D
MAF!M0[/>3_M/'8'%?3[DT=&\D&&&TMPZ[VF`3<9Y:BDLON..3N
=5[J(W=R#;W-S^>RCA=<*/JG87#QK'>GHBOI-%*G`??6NZM_C4?&
M`BIYOYLA4Y\W8L%XJ&0T>5&%0;2,Y(WC3G3.KAI/:I+L<3R)-[;OR43O_.94
MLY*U5+T[6#7J86VFCSE6C`@YI\O$OZ[8'18J?IEHVJ1&W"VA3RZC6F^A<>7Y
ME/L\1<(H$82^=CTS/<]\2!`?9[T2MY;V@Y(Q,SOKLRI=,_HVYM36%8X^T]3_
MX^)19^;UK@>D4T%G<_69@"]F)2TIV+6LUFN(*J9`S>NU;"Z4SC:._`067;=3
M6.)?/.OXH?_XEQ[X.=O:$]^L@;8Z:+S[)A^Y20X2,`SCX$+JL]I++KY*
Goodwill and Other Intangible Assets (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Other Intangible Assets [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Intangible Assets |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aggregate amortization expense |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Estimated amortization expense related to intangible assets |
|
Fair Value Measurements (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carrying value and fair value of variable rate long-term debt |
|
Lines of Business
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lines of Business [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lines of Business |
9. Lines of Business
Our reportable segments are Animal Hospital, Laboratory and Medical Technology. These
segments are strategic business units that have different services, products and/or functions. The
segments are managed separately because each is a distinct and different business venture with
unique challenges, risks and rewards. Our Animal Hospital segment provides veterinary services for
companion animals and sells related retail and pharmaceutical products. Our Laboratory segment
provides diagnostic laboratory testing services for veterinarians, both associated with our animal
hospitals and those independent of us. Our Medical Technology segment sells digital radiography
and ultrasound imaging equipment, related computer hardware, software and ancillary services to the
veterinary market. We also operate a corporate office that provides general and administrative
support services for our other segments.
The accounting policies of our segments are essentially the same as those described in the
summary of significant accounting policies included in our 2010 Annual Report on Form 10-K. We
evaluate the performance of our segments based on gross profit and operating income. For purposes
of reviewing the operating performance of our segments all intercompany sales and purchases are
generally accounted for as if they were transactions with independent third parties at current
market prices.
The following is a summary of certain financial data for each of our segments (in thousands):
|
Fair Value Measurements (Details) (USD $)
In Thousands |
Jun. 30, 2011
|
Dec. 31, 2010
|
---|---|---|
Carrying value and fair value of long-term debt | ||
Variable-rate long-term debt, Carrying Value | $ 481,250 | $ 493,750 |
Variable-rate long-term debt, Fair Value | $ 483,055 | $ 496,219 |
Subsequent Events
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Subsequent Events [Abstract] | |
Subsequent Events |
13. Subsequent Events
On July 10, 2011, we entered into a material definitive agreement with MediMedia USA, Inc.
(“MediMedia”) to acquire all of the issued and outstanding membership interests in MediMedia Animal
Health, LLC (“Vetstreet”) from MediMedia for $146 million in cash, subject to adjustment for
working capital and Vetstreet indebtedness. Vetstreet is the nation’s largest provider of online
communications, professional education and marketing solutions to the veterinary community. We
plan to refinance our senior credit facility to include an
incremental $100 million to finance a portion of this transaction.
The acquisition is expected to close in August 2011. The acquisition of Vetstreet expands the breadth of our product offerings to the veterinary
community and provides long-term synergies to our existing businesses.
On July 11, 2011, we acquired BrightHeart Veterinary Centers (“BrightHeart”) for approximately
$50 million in cash. BrightHeart operates nine animal hospitals, eight of which focus on the
delivery of specialty and emergency medicine. The acquisition will increase our level of market
recognition in areas where we have an existing market presence.
|